Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.76 USD

88.76
5,165,991

-0.24 (-0.27%)

Updated Oct 28, 2024 04:00 PM ET

After-Market: $88.76 0.00 (0.00%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Is Gilead Sciences (GILD) a Great Stock for Value Investors?

Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

Mergers & Acquisitions Take Center Stage in Biotech Industry

Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.

Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss

Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.

Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.

Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus

Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q2 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.

Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised

Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.

Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 4.60% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

Buy 6 Top Stocks Set to Beat on Earnings in Q2 Today

Second-quarter 2019 earnings expectations have improved this month. In spite of a prolonged trade conflict with China, we do not see a broad-based decline in guidance by U.S. corporates.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.

Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?

On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.

Guardant Health (GH) to Report Q2 Earnings: What's in Store?

Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.

What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.

What's in the Cards for Pfizer (PFE) This Earnings Season?

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.

Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?

Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.

Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.

Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.

Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?

Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.

5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.